Acurx announces new bile acid and microbiome analyses from ph2b trial of ibezapolstat in cdi patients presented at idweek scientific conference

The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with c. difficile infection (cdi) ibezapolstat treatment of patients with cdi is associated with the restoration of beneficial bacterial classes in the gut preparation continues to advance ibezapolstat into international phase 3 clinical trials for treatment of c.
ACXP Ratings Summary
ACXP Quant Ranking